Literature DB >> 16946018

MD-2 expression is not required for cell surface targeting of Toll-like receptor 4 (TLR4).

Alberto Visintin1, Kristen A Halmen, Naseema Khan, Brian G Monks, Douglas T Golenbock, Egil Lien.   

Abstract

The cell surface receptor complex formed by TLR4 and myeloid differentiation 2 (MD-2) is engaged when cells are exposed to LPS. Recent studies suggested that surface localization of functional mouse TLR4 (mTLR4) depends on the simultaneous expression of MD-2. As we did not observe a similar requirement, we conducted a comparative study of human TLR4 and mTLR4 surface expression in immune cells derived from the MD-2 knockout mouse and LPS-responsive cell lines and in cells that ectopically express TLR4. Our results indicate that in the human and mouse models, neither TLR4 function nor TLR4 surface targeting requires MD-2 coexpression. Accordingly, we report on one human cell line, which constitutively expresses functional TLR4 on the cell surface in the absence of MD-2 expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946018     DOI: 10.1189/jlb.0606388

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  20 in total

1.  Eradication of the commensal intestinal microflora by oral antimicrobials interferes with the host response to lipopolysaccharide.

Authors:  T Umenai; H Hirai; N Shime; T Nakaya; T Asahara; K Nomoto; M Kita; Y Tanaka; J Imanishi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-03-20       Impact factor: 3.267

2.  Interferon-gamma-induced MD-2 protein expression and lipopolysaccharide (LPS) responsiveness in corneal epithelial cells is mediated by Janus tyrosine kinase-2 activation and direct binding of STAT1 protein to the MD-2 promoter.

Authors:  Sanhita Roy; Yan Sun; Eric Pearlman
Journal:  J Biol Chem       Date:  2011-05-13       Impact factor: 5.157

3.  Expression of functional D299G.T399I polymorphic variant of TLR4 depends more on coexpression of MD-2 than does wild-type TLR4.

Authors:  Polonca Prohinar; Prasad Rallabhandi; Jerrold P Weiss; Theresa L Gioannini
Journal:  J Immunol       Date:  2010-03-08       Impact factor: 5.422

4.  Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice.

Authors:  Timea Csak; Arumugam Velayudham; Istvan Hritz; Jan Petrasek; Ivan Levin; Dora Lippai; Donna Catalano; Pranoti Mandrekar; Angela Dolganiuc; Evelyn Kurt-Jones; Gyongyi Szabo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-01-13       Impact factor: 4.052

5.  Bone marrow chimeras and c-fms conditional ablation (Mafia) mice reveal an essential role for resident myeloid cells in lipopolysaccharide/TLR4-induced corneal inflammation.

Authors:  Holly R Chinnery; Eric C Carlson; Yan Sun; Michelle Lin; Sandra H Burnett; Victor L Perez; Paul G McMenamin; Eric Pearlman
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

6.  Phagocytosis and intracellular killing of MD-2 opsonized gram-negative bacteria depend on TLR4 signaling.

Authors:  Vishal Jain; Annett Halle; Kristen A Halmen; Egil Lien; Marie Charrel-Dennis; Sanjay Ram; Douglas T Golenbock; Alberto Visintin
Journal:  Blood       Date:  2008-01-18       Impact factor: 22.113

7.  Novel roles of lysines 122, 125, and 58 in functional differences between human and murine MD-2.

Authors:  Jozica Vasl; Alja Oblak; Theresa L Gioannini; Jerrold P Weiss; Roman Jerala
Journal:  J Immunol       Date:  2009-09-25       Impact factor: 5.422

8.  Lipopolysaccharide directly alters renal tubule transport through distinct TLR4-dependent pathways in basolateral and apical membranes.

Authors:  David W Good; Thampi George; Bruns A Watts
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-22

Review 9.  Toll-like receptors at the ocular surface.

Authors:  Eric Pearlman; Angela Johnson; Gautam Adhikary; Yan Sun; Holly R Chinnery; Todd Fox; Mark Kester; Paul G McMenamin
Journal:  Ocul Surf       Date:  2008-07       Impact factor: 5.033

10.  Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564).

Authors:  Yan Sun; Eric Pearlman
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-20       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.